Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: BMRA 0 – 5 AYTU (1 Tie) Matrix Metrics: BMRA 1 – 9 AYTU

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs AYTU
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 29
RSI-14: 28.9 · SMA20: $1.62 · SMA50: $1.96
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (BMRA 0 – 5 AYTU)

Columns: Metric · BMRA · AYTU
1. Valuation Multiples AYTU
Forward P/E N/M 9.2x
Trailing P/E N/M 9.2x
PEG Ratio N/M N/M
EV / Revenue 1.1x 0.3x
2. Growth & Scale AYTU
Revenue Growth (YoY) -8.3% +6.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.3M $58M
Market Cap $6.0M $19.6M
3. Profitability & Quality AYTU
Gross Margin 0.9% 64.0%
Operating Margin -125.2% -14.4%
Net Profit Margin -115.5% -24.8%
Return on Equity (ROE) -113.8% -52.5%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$3.2M -$1.4M
Cash Flow Margin -73.5% -2.4%
Net Cash / Leverage $1.1M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity N/A 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (1) vs AYTU (9)
Institutional Metric BMRA AYTU Criterion Row Edge
Market Capitalization
Scale
$6.0M $19.6M Larger Scale AYTU
Trailing P/E Ratio
Valuation
N/M 9.2x Lower Multiple AYTU
Forward P/E Ratio
Valuation
N/M 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
-8.3% +6.4% Higher Growth AYTU
Operating Margin (TTM)
Profitability
-125.2% -14.4% Higher Margin AYTU
Net Profit Margin
Profitability
-115.5% -24.8% Higher Margin AYTU
Return on Equity (ROE)
Capital Efficiency
-113.8% -52.5% Higher ROE AYTU
52-Week Range Position
Momentum
5% ($1–$3) 5% ($2–$3) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AYTU +15.22 pp
BMRA: -26.49% · AYTU: -11.27%
3M Horizon BMRA +8.31 pp
BMRA: -15.0% · AYTU: -23.31%
6M Horizon AYTU +25.75 pp
BMRA: -39.56% · AYTU: -13.81%
1Y Horizon AYTU +33.46 pp
BMRA: -45.6% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue AYTU Revenue BMRA Op. Margin AYTU Op. Margin Margin Leader
FY2019 $10M $10M -46.4% -230.1% BMRA
FY2020 $10M $30M -41.0% -76.5% BMRA
FY2021 $10M $70M -104.2% -89.7% AYTU
FY2022 $20M $100M -24.0% -113.7% BMRA
FY2023 $10M $110M -135.3% -15.9% AYTU
FY2024 $10M $70M -117.6% -2.4% AYTU
FY2025 $10M $70M -96.7% -11.8% AYTU
FY2026 $0M $60M -119.5% -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AYTU leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.